Mitapivat · Pyrukynd

Small molecule

Also known as AG-348

Approvedregulatory verdict

Evidence outlook

Approved: Pyruvate Kinase Deficiency

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

Latest reported trial: NCT03548220 · Phase 3 · met primary endpoint · grade pending

Also in development:Sickle Cell Disease · Phase 3 · investigational in the US · under FDA reviewTransfusion-Dependent Beta Thalassemia · Phase 3 · investigational in the USapproved in the US as Aqvesme (same FDA application)

Also approved (5)
EU
  • Adults with anemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassemia (release dated 2026-05-22)biospace.com
  • Treatment of pyruvate kinase deficiency (PK deficiency) in adult patients (holder Agios Netherlands B.V.)EMA
Product first approved 2022
AE
  • Adults with non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia (Agios release dated 2026-03-02)
Product first approved 2026biospace.com
SA
  • Adults with non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia (Agios release dated 2025-08-04)
Product first approved 2025finviz.com
UK
  • Treatment of PK deficiency in adult patients (Great Britain, via EC Decision Reliance Procedure)
biospace.com

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (8)
Pyruvate Kinase Deficiency
NCT05175105 · Agios Pharmaceuticals, Inc.
2022-06-06 – 2030-01 · Pediatric Pyruvate Kinase Deficiency, Pediatric Hemolytic Anemia
What this study did
NCT05144256 · Agios Pharmaceuticals, Inc.
2022-06-08 – 2029-06 · Pediatric Pyruvate Kinase Deficiency, Pediatric Hemolytic Anemia
What this study did
NCT03853798 · Agios Pharmaceuticals, Inc.
2019-03-21 – 2024-07-03 · Pyruvate Kinase Deficiency
What this study did
Sickle Cell Disease
Transfusion-Dependent Beta Thalassemia
Other / comorbidity
NCT07517133 · Agios Pharmaceuticals, Inc.
2026-09 – 2032-03 · Non-Transfusion-dependent Alpha-Thalassemia, Non-Transfusion-dependent Beta-Thalassemia
What this study did
Phase 2/3 (1)
Sickle Cell Disease
Phase 2 (5)
Pyruvate Kinase Deficiency
NCT02476916 · Agios Pharmaceuticals, Inc.
2015-06-26 – 2025-04-02 · Pyruvate Kinase Deficiency
What this study did
Sickle Cell Disease
NCT06286046 · Agios Pharmaceuticals, Inc.
2026-03 – 2028-12 · Sickle Cell Disease, Nephropathy
What this study did
Other / comorbidity
NCT03692052 · Agios Pharmaceuticals, Inc.
2019-03-20 – 2030-09-30 · Thalassemia
What this study did
NCT07055243 · University Health Network, Toronto
2025-10-20 – 2029-10 · Anemia
What this study did
NCT05935202 · EuroBloodNet Association
2023-12-21 – 2029-03-30 · Hereditary Red Blood Cell Disorder (Disorder)
What this study did
Phase 1/2 (1)
Sickle Cell Disease
NCT04610866 · National Heart, Lung, and Blood Institute (NHLBI)
2020-12-09 – 2028-02-28 · Sickle Cell Disease, Hemolytic Anemia
What this study did
Phase 1 (12)
Sickle Cell Disease
NCT04000165 · National Institutes of Health Clinical Center (CC)
2019-07-11 – 2021-06-21 · Sickle Cell Disease
What this study did
Other / comorbidity
NCT06648824 · Agios Pharmaceuticals, Inc.
2024-10-17 – 2024-12-03 · Healthy Participants
What this study did
NCT05610657 · Agios Pharmaceuticals, Inc.
2023-01-10 – 2023-07-21 · Moderate Hepatic Impairment
What this study did
NCT04696393 · Agios Pharmaceuticals, Inc.
2021-01-06 – 2021-03-19 · Healthy Volunteers
What this study did
NCT04565678 · Agios Pharmaceuticals, Inc.
2020-09-21 – 2020-12-03 · Healthy Volunteers
What this study did
NCT04472832 · Agios Pharmaceuticals, Inc.
2020-06-17 – 2020-11-23 · Healthy Volunteers
What this study did
NCT03991312 · Agios Pharmaceuticals, Inc.
2019-06-20 – 2019-09-10 · Healthy Volunteers
What this study did
NCT03397329 · Agios Pharmaceuticals, Inc.
2017-10-03 – 2017-11-13 · Healthy Volunteers
What this study did
NCT03250598 · Agios Pharmaceuticals, Inc.
2017-08-09 – 2017-10-09 · Healthy, Japanese, Non-Asian
What this study did
NCT02149966 · Agios Pharmaceuticals, Inc.
2014-05 – 2014-11 · Healthy Volunteer
What this study did
NCT02108106 · Agios Pharmaceuticals, Inc.
2014-03 – 2014-08 · Healthy Volunteer
What this study did
Phase 4 (1)
Pyruvate Kinase Deficiency
NCT05777993 · Agios Pharmaceuticals, Inc.
2023-07-06 – 2031-08 · Pyruvate Kinase Deficiency, Anemia, Hemolytic, Sickle Cell Disease, Thalassemia
What this study did

Competitive landscape

2 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Transfusion-Dependent Beta Thalassemia: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Mitapivat (Pyrukynd): this drugPhase 3Small moleculePyruvate kinasenot yet gradedNo reviewed efficacy summary in this indication
Exagamglogene Autotemcel (Casgevy)ApprovedGene therapy / editingBCL11A erythroid enhancer (gene editing)not yet gradedNo reviewed efficacy summary in this indication
Mitapivat (Aqvesme)ApprovedSmall moleculePyruvate kinasePartial signal
NCT04770779: Transfusion reduction response in the double-blind period (baseline through Week 48), mitapivat vs placebo: 30.4% vs 12.6%, common risk difference 17.6 percentage points (95% CI 8.0 to 27.2), p=0.0003 (CT.gov posted results).
NCT04770753: Hemoglobin response from Week 12 through Week 24 in the double-blind period, mitapivat vs placebo: 42.3% vs 1.6%, difference 40.9 percentage points (95% CI 32.0 to 49.8), p<0.0001 (CT.gov posted results).
Renizgamglogene AutogedtemcelDiscontinuedGene or cell therapy (subtype unspecified)HBG1/HBG2 promotersnot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(7 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Pyrukynd (Mitapivat) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (2)
February 2028 (1)
Phase 1/2Sickle Cell DiseaseActive not recruiting
Est. primary completion 2028-02-28 · NCT04610866 · CT.gov ↗
What to watch
September 2028 (1)
Phase 2Hereditary Red Blood Cell Disorder (Disorder)Active not recruiting
Est. primary completion 2028-09-30 · NCT05935202 · CT.gov ↗
What to watch
2029 (5)
March 2029 (1)
Phase 3Non-Transfusion-dependent Alpha-Thalassemia, Non-Transfusion-dependent Beta-ThalassemiaRecruiting
Est. primary completion 2029-03 · NCT07517133 · CT.gov ↗
What to watch
June 2029 (1)
Phase 3Transfusion-Dependent Beta ThalassemiaRecruiting
Est. primary completion 2029-06 · NCT07506863 · CT.gov ↗
What to watch
August 2029 (2)
Phase 3Sickle Cell DiseaseRecruiting
Est. primary completion 2029-08 · NCT07656415 · CT.gov ↗
What to watch
Phase 4Sickle Cell DiseaseEnrolling by invitation
Est. primary completion 2029-08 · NCT05777993 · CT.gov ↗
What to watch
October 2029 (1)
Phase 2AnemiaActive not recruiting
Est. primary completion 2029-10 · NCT07055243 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(3)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Coming up

1 February 2027FDA action dateMitapivat sickle cell sNDA PDUFA goal date extended to 1 February 2027
US, FDA · Source ↗

Recent

12 May 2026Filing submittedAgios submits mitapivat sNDA for sickle cell disease
US, FDA · AGIOS PHARMACEUTICALS, INC. · Source ↗
November 2025Topline resultRISE UP Phase 3 of mitapivat in sickle cell disease (NCT05031780): hemoglobin response met; pain crisis rate not significant
Agios Pharmaceuticals, Inc. · Source ↗